

Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2014

Author Details

^{1,2}A/Prof Geoffrey W Coombs, ³Ms Denise A Daley, ¹Ms Yung Thin Lee, ^{1,2}Dr Stanley Pang, ²Ms Julie C Pearson ^{1,2} Dr J Owen Robinson, ⁴Prof Paul DR Johnson, ⁵Ms Despina Kotsanas, ⁶Ms Jan M Bell, ^{6,7}Prof John D Turnidge for the Australian Group on Antimicrobial Resistance

¹Australian Collaborating Centre for *Enterococcus* and *Staphylococcus* Species (**ACCESS**) Typing and Research, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia

²Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

³Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

⁴Microbiology and Infectious Diseases Departments, Austin Health, Heidelberg, Victoria, Australia

⁵Infectious Diseases, Monash Health, Monash Medical Centre, Clayton, Victoria

⁶SA Pathology, Microbiology and Infectious Diseases, Women's and Children's Hospital, North Adelaide, South Australia, Australia

⁷Departments of Pathology, Paediatrics and Molecular and Biomedical Sciences, University of Adelaide, Adelaide, South Australia, Australia

Corresponding Author

A/Prof Geoffrey Coombs

Australian Collaborating Centre for *Enterococcus* and *Staphylococcus* Species (**ACCESS**) Typing and Research, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia

Telephone: +61 8 6152 2397

Email: geoffrey.coombs@health.wa.gov.au

Word Count

2,227

Keywords

Australian Group on Antimicrobial Resistance (AGAR); antimicrobial resistance surveillance; *Enterococcus faecium*, *Enterococcus faecalis*, Vancomycin Resistant Enterococci (VRE), Bacteraemia

Abstract

From 1st January to 31st December 2014 27 institutions around Australia participated in the Australian Enterococcal Sepsis Outcome Programme (AESOP). The aim of AESOP 2014 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to characterise the molecular epidemiology of the *E. faecium* isolates. Of the 952 unique episodes of bacteraemia investigated, 94.8% were caused by either *E. faecalis* (54.9%) or *E. faecium* (39.9%). Ampicillin resistance was detected in 0.6% of *E. faecalis* and in 90.5% of *E. faecium*. Vancomycin non-susceptibility was reported in 0.2% and 46.1% of *E. faecalis* and *E. faecium* respectively. Overall 50.1% of *E. faecium* harboured *vanA* or *vanB* genes. For the *vanA/B* positive *E. faecium* isolates, 81.2% harboured *vanB* genes and 18.8 % *vanA* genes. The percentage of *E. faecium* bacteraemia isolates resistant to vancomycin in Australia is significantly higher than that seen in most European countries. *E. faecium* consisted of 113 PFGE pulsotypes of which 68.9% of isolates were classified into 14 major pulsotypes containing five or more isolates. Multilocus sequence typing grouped the 14 major pulsotypes into clonal cluster 17, a major hospital-adapted polyclonal *E. faecium* cluster. The geographical distribution of the four predominant sequence types (ST203, ST796, ST555 and ST17) varied with only ST203 identified across most regions of Australia. Overall 73.7% of isolates belonging to the four predominant STs harboured *vanA* or *vanB* genes. In conclusion, the AESOP 2014 has shown enterococcal bacteraemias in Australia are frequently caused by polyclonal ampicillin-resistant

high-level gentamicin resistant *vanA* or *vanB* *E. faecium* which have limited treatment options.

Background

Globally enterococci are thought to account for approximately 10% of all bacteraemias, and in North America and Europe is the fourth and fifth leading cause of sepsis respectively.^{1,2} Although in the 1970s healthcare-associated enterococcal infections were primarily due to *Enterococcus faecalis*, there has been a steadily increasing prevalence of *E. faecium* nosocomial infections.³⁻⁵ Worldwide the increase in nosocomial *E. faecium* infections has primarily been due to the expansion of polyclonal hospital-adapted clonal complex (CC) 17 strains. While innately resistant to many classes of antibiotics, *E. faecium* has demonstrated a remarkable capacity to evolve new antimicrobial resistances. In 2009 the Infectious Diseases Society of America highlighted *E. faecium* as one of the key problem bacteria or ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter species*) pathogens requiring new therapies.⁶

The Australian Group on Antimicrobial Resistance (AGAR) is a network of laboratories located across Australia that commenced surveillance of antimicrobial resistance in *Enterococcus* species in 1995.⁷ In 2011 AGAR commenced the Australian Enterococcal Sepsis Outcome Programme (AESOP).⁸ The objective of AESOP 2014 was to determine the proportion of *E.*

faecalis and *E. faecium* bacteraemia isolates demonstrating antimicrobial resistance with particular emphasis on:

1. Assessing susceptibility to ampicillin
2. Assessing susceptibility to glycopeptides
3. Molecular epidemiology of *E. faecium*

Methodology

Participants: Twenty-seven laboratories from all eight Australian states and territories.

Collection Period: From 1st January to 31st December 2014, the 27 laboratories collected all enterococcal species isolated from blood cultures. Enterococci with the same species and antimicrobial susceptibility profiles isolated from a patient's blood culture within 14 days of the first positive culture were excluded. A new enterococcal sepsis episode in the same patient was recorded if it was confirmed by a further culture of blood taken more than 14 days after the initial positive culture. Data were collected on age, sex, date of admission and discharge (if admitted), and mortality at 30 days from date of blood culture collection. To avoid interpretive bias, no attempt was made to assign attributable mortality. Each episode of bacteraemia was designated as "hospital onset" if the first positive blood culture(s) in an episode was collected >48 hours after admission.

Laboratory Testing: Enterococcal isolates were identified to the species level by the participating laboratories using one of the following methods: API 20S (bioMérieux), API ID32Strep (bioMérieux), Vitek2[®] (bioMérieux), Phoenix[™] (BD), matrix-assisted laser desorption ionization (MALDI) Biotyper (Bruker Daltonics), Vitek-MS (bioMérieux), PCR, or conventional biochemical tests. Antimicrobial susceptibility testing was performed by using the Vitek2[®] (bioMérieux, France) or the Phoenix[™] (BD, USA) automated microbiology systems according to the manufacturer's instructions. Minimum inhibitory concentration (MIC) data and isolates were referred to the Australian Collaborating Centre for *Enterococcus* and *Staphylococcus* Species (ACCESS) Typing and Research. Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were utilised for interpretation.^{9,10} Isolates with either a resistant or an intermediate category were classified as non-susceptible. Linezolid and daptomycin non-susceptible isolates and selected vancomycin susceptible isolates were retested by Etest[®] (bioMérieux, France) using the Mueller-Hinton agar recommended by the manufacturer. *E. faecalis* ATCC[®] 29212 was used as the control strain. Molecular testing including *vanA/B* PCR, pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) was performed as previously described.¹¹⁻¹³

A chi-square test for comparison of two proportions was performed and 95% confidence intervals (95% CI) were determined using MedCalc for Windows, version 12.7 (Medcalc Software, Ostend Belgium).

Approval to conduct the prospective data collection was given by the research ethics committee associated with each participating laboratory.

Results

From 1st January to 31st December 2014, 952 unique episodes of enterococcal bacteraemia were identified. Although ten *Enterococcus* species were identified, 54.9% (523 isolates) were *E. faecalis* and 39.9% (380 isolates) were *E. faecium*. Forty-nine enterococci were identified either as *Enterococcus casseliflavus* (19 isolates), *E. gallinarum* (13), *E. avium* (9), *E. hirae* (2), *E. raffinosus* (3), *E. durans* (1), *E. cecorum* (1), and *E. mundtii* (1).

A significant difference was seen in patient sex ($p < 0.0001$) with 613 (64.4%) being male (95% CI, 61.4 – 67.5). The average age of patients was 63 years ranging from 0 – 100 years with a median age of 67 years. Of the 952 episodes 474 (49.8%) were hospital onset (95% CI, 46.5 – 52.9). However a significant difference was seen between *E. faecium* and *E. faecalis*, with 71.8% (95% CI, 67.0 – 76.3) of *E. faecium* episodes being hospital onset compared to 36.5% (95% CI, 32.4 – 40.8) for *E. faecalis* ($p < 0.0001$). All-cause mortality at 30 days was 18.5% (95% CI, 15.9 – 21.3). There was a significant difference in mortality between *E. faecalis* and *E. faecium* episodes (13.2% [95% CI, 10.3 – 16.6] vs 27.6% [95% CI, 22.9 – 32.7] respectively, $p < 0.0001$) and between vancomycin

susceptible and vancomycin non-susceptible *E. faecium* episodes (22.8% [95% CI, 16.9 – 29.6] vs 32.9% [95% CI, 25.7 – 40.7] respectively, p=0.05).

***E. faecalis* Phenotypic Susceptibility Results:** Apart from erythromycin, tetracycline, ciprofloxacin and high-level gentamicin, acquired resistance was rare amongst *E. faecalis* (Table 1). Ampicillin resistance was detected in three isolates and only one isolate was vancomycin non-susceptible. Thirty six (6.9%) *E. faecalis*, were initially reported as linezolid non-susceptible (CLSI breakpoint >2 mg/L). However by Etest[®] 22 of the 35 isolates available for MIC testing by Etest[®] had a linezolid MIC of ≤2 mg/L and were therefore considered linezolid susceptible. Thirteen isolates with an MIC of 4 mg/L although non-susceptible by CLSI guidelines were considered susceptible by EUCAST guidelines. Eight (1.6%) isolates were initially reported non-susceptible to daptomycin (CLSI and EUCAST breakpoint >4 mg/L). However by Etest[®] seven of the eight isolates had an MIC of <4 mg/L and were therefore considered susceptible. One isolate had an MIC of 8 mg/L which is considered non-susceptible. All isolates were susceptible to teicoplanin.

***E. faecium* Phenotypic Susceptibility Results:** The majority of *E. faecium* were non-susceptible to multiple antimicrobials (Table 2). Most isolates were non-susceptible to ampicillin, erythromycin, tetracycline, ciprofloxacin, nitrofurantoin and high-level gentamicin. Overall 175 (46.1%) were phenotypically vancomycin non-susceptible (MIC >4 mg/L). Thirty one (8.2%)

and thirty three (8.8%) isolates were teicoplanin non-susceptible by CLSI and EUCAST guidelines respectively. Nine (2.4%) isolates were initially reported as linezolid non-susceptible (CLSI breakpoint >2 mg/L). However by Etest[®] seven of the nine isolates had a linezolid MIC of ≤2 mg/L. One isolate had an MIC of 4mg/L which was considered susceptible by EUCAST guidelines but non-susceptible by CLSI guidelines. One isolate had an MIC of 8 mg/L which was considered non-susceptible by CLSI and EUCAST guidelines.

Genotypic Vancomycin Susceptibility Results: *vanA/vanB* PCR was performed on 512 of the 523 *E. faecalis* isolates. Overall seven (1.4%) of the 512 isolates harboured a *vanA* or *vanB* gene. The vancomycin non-susceptible *E. faecalis* isolate (Vitek[®] vancomycin MIC ≥32 mg/L) harboured a *vanB* gene. One phenotypically vancomycin/teicoplanin susceptible isolate (Vitek[®] vancomycin MIC = 1 mg/L, teicoplanin MIC = ≤0.5 mg/L) harboured *vanA*. A further five phenotypically vancomycin susceptible *E. faecalis* isolates (Vitek[®] vancomycin MIC = 1) harboured *vanB* genes.

vanA/B PCR was performed on 371 of the 380 *E. faecium* isolates, including 172 of the 175 vancomycin non-susceptible isolates and 199 of the 205 vancomycin susceptible isolates. Overall 186 (50.1%) of the 371 isolates harboured a *vanA* or *vanB* gene.

Thirty one of the vancomycin non-susceptible *E. faecium* isolates harboured *vanA* (Vitek[®] vancomycin MIC = 8mg/L [one isolate] and >16mg/L [30 isolates]). A further 137 *E. faecium* vancomycin non-susceptible isolates harboured *vanB* (Vitek[®] vancomycin MIC = 8 mg/L [two isolates] and >16mg/L [135 isolates]). Neither *vanA* nor *vanB* genes were detected in four vancomycin non-susceptible isolates (Vitek[®] vancomycin MIC \geq 32 mg/L, Etest[®] vancomycin MIC >256 mg/L).

vanA or *vanB* genes were detected in 18 vancomycin susceptible *E. faecium* isolates. Four isolates harboured *vanA* (Vitek[®] vancomycin MIC \leq 0.5mg/L [two isolates], MIC = 1 mg/L [one isolate] and MIC = 2 mg/L [one isolate], teicoplanin \leq 1mg/L [4 isolates]). Fourteen isolates harboured *vanB* (Vitek[®] vancomycin MIC \leq 0.5mg/L [seven isolates], MIC = 1 mg/L [six isolates] and MIC = 2 mg/L [one isolate]).

Of the 151 *vanB E. faecium* isolates, three were teicoplanin resistant (MIC >32 mg/L).

***E. faecium* Molecular Epidemiology:** Of the 380 episodes, 370 *E. faecium* isolates were available for typing. By PFGE 367 isolates were classified into 113 pulsotypes including 14 major pulsotypes with five or more isolates (Table 3). Three isolates were not typable by PFGE. Of the 99 pulsotypes with <5 isolates, 90 had only one isolate. Overall 253 (68.9%) of the 367 isolates were grouped

into the 14 major pulsotypes from which nine multilocus sequence types (STs) were identified. Using eBURST, the nine STs were grouped into CC 17.

Geographical distribution of the nine STs varied (Table 3). For the four most prominent STs, ST203 (69 isolates) was identified across most of Australia, ST796 (64 isolates) primarily in Victoria, ST555 (46 isolates) primarily in South Australia and Western Australia and ST17 (34 isolates) primarily in New South Wales. For the remaining five STs, ST117 (16 isolates) was found in New South Wales, Queensland and the Australian Capital Territory, ST 761 (7 isolates) in New South Wales and Queensland, ST192 (6 isolates) in Victoria and Tasmania, ST80 (6 isolates) in New South Wales and Western Australia and ST341 (5 isolates) in New South Wales and the Australian Capital Territory.

vanA was detected in two major pulsotypes (29 isolates, Efm18 and Efm85), and *vanB* in eight major pulsotypes (137 isolates, Efm1, Efm2, Efm3, Efm18, Efm74, Efm75, Efm76, Efm77) (Table 4). Efm18 (ST17) harboured *vanA* and *vanB* genes. Twelve minor pulsotypes (14 isolates) also harboured *vanB* genes. In addition *vanA* genes were detected in six minor pulsotypes (six isolates).

Discussion

Enterococci are intrinsically resistant to a broad range of antimicrobials including the cephalosporins and sulphonamides. By their ability to acquire additional

resistance through the transfer of plasmids and transposons and to disseminate easily in the hospital environment enterococci have become difficult to treat and provide major infection control challenges.

As the AGAR programs are similar to those conducted in Europe (http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx) comparison of Australia antimicrobial resistance data with other countries is possible.

In the 2013 European Centre for Disease Prevention and Control and Prevention (ECDC) Enterococci surveillance program the European Union/European Economic Area (EU/EEA) population-weighted mean percentage of *E. faecium* resistant to vancomycin was 8.9% (95% CI, 7 – 12), ranging from 0.0% (95% CI, 0 – 9) in Estonia, Lithuania, Malta and Sweden to 42.7% (95% CI, 38 – 48) in Ireland. Cyprus (23.3%), United Kingdom (23.3%), Portugal (22.0%) and Greece (21.2%) were the only other EU/EEA countries to report above 20%.

(<http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf>).

In AESOP 2014 approximately 40% of enterococcal bacteraemia were due to *E. faecium* of which 46.1% (95% CI, 41.0 – 51.2) were phenotypically vancomycin non-susceptible by Vitek2[®] or Phoenix[™]. However 50.1% of *E. faecium* isolates tested (186/371) harboured *vanA/vanB* genes, of which 81.2% were *vanB*.

Overall 9.4% (35/371) of *E. faecium* isolates harboured a *vanA* gene which is a significant increase from the 2.6% (8/310) of isolates reported in AESOP 2013 ($p= 0.0005$).¹⁴ The majority of *E. faecium* isolates were also non-susceptible to multiple antimicrobials including ampicillin, erythromycin, tetracycline, ciprofloxacin and high level gentamicin. In AESOP 2011¹⁵ and 2013¹⁴, 37.0% and 48.6% of *E. faecium* harboured *vanA/vanB* respectively confirming the incidence of vancomycin resistant *E. faecium* bacteraemia in Australia is increasing.

Fourteen (9.3%) of the 151 *vanB E. faecium* isolates had a vancomycin MIC at or below the CLSI and the EUCAST susceptible breakpoint (≤ 4 mg/L) and would not have been identified using routine phenotypic antimicrobial susceptibility methods. Furthermore six *vanA/B E. faecalis* were also phenotypically vancomycin susceptible (MIC 1 mg/L). *vanA/B* genes were not detected in four *E. faecium* isolates with a MIC >256 mg/L.

By PFGE, *E. faecium* was shown to be very polyclonal, consistent with the known plasticity of the enterococcal genome. The 14 major *E. faecium* pulsotypes formed part of CC17, a global hospital-derived lineage that has successfully adapted to hospital environments. CC17 is characteristically ampicillin and quinolone resistant and subsequent acquisition of *vanA*- or *vanB*-containing transposons by horizontal transfer in CC17 clones has resulted in VRE with pandemic potential. In AESOP 2014 four *E. faecium* STs

predominated: ST203 (of which 74% of isolates harboured *vanB* genes); ST796 (100% harboured *vanB*); ST555 (37% harboured *vanB*); and ST17 (71% harboured *vanA* and 3% harboured *vanB*). Two minor PFGE pulsotypes identified in AESOP 2013 have become major pulsotypes in AESOP 2014: Efm80 – ST117 (16 isolates) found in New South Wales (11 isolates), Australia Capital Territory (4 isolates) and Queensland (1 isolate) and Efm85 – ST80 (6 isolates), in New South Wales (5 isolates) and Western Australia (1 isolate). The majority of Efm85 – ST80 isolates harboured *vanA* genes.

Conclusions

The AESOP 2014 study has shown that although predominately caused by *E. faecalis*, enterococcal bacteraemia in Australia is frequently caused by ampicillin-resistant high-level gentamicin-resistant *vanB E. faecium*. Furthermore the percentage of *E. faecium* bacteraemia isolates resistant to vancomycin in Australia is significantly higher than that seen in almost all European countries. Although the *vanB* operon continues to be the predominant genotype, the number of *vanA E. faecium* identified in AESOP 2014 has significantly increased when compared to AESOP 2013. In addition to being a significant cause of healthcare-associated sepsis, the emergence of multiple multi-resistant hospital-adapted *E. faecium* strains has become a major infection control issue in Australian hospitals. Further studies on the enterococcal genome will contribute to our understanding of the rapid and ongoing evolution of enterococci in the hospital environment and assist in preventing their nosocomial transmission.

Acknowledgments

This study was primarily funded by a grant from the Australian Government Department of Health.

We gratefully acknowledge Yung Ching Lee from the Department of Microbiology, PathWest Laboratory Medicine – WA, Fiona Stanley Hospital.

Members of the AGAR in 2014 were:

Australian Capital Territory

Peter Collignon and Susan Bradbury, The Canberra Hospital

New South Wales

Thomas Gottlieb and Graham Robertson, Concord Hospital

James Branley and Donna Barbaro, Nepean Hospital

George Kotsiou and Peter Huntington, Royal North Shore Hospital

Sebastian van Hal and Bradley Watson, Royal Prince Alfred Hospital

David Mitchell and Lee Thomas, Westmead Hospital

Rod Givney and Ian Winney, John Hunter Hospital

Northern Territory

Rob Baird and Jann Hennessy, Royal Darwin Hospital

Queensland

Enzo Binotto and Bronwyn Thomsett, Pathology Queensland Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology Queensland Central Laboratory

Petra Derrington and Sharon Dal-Cin, Pathology Queensland Gold Coast Hospital

Robert Horvath, Pathology Queensland Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology Queensland Princess Alexandra Hospital

Jenny Robson and Georgia Peachey, Sullivan Nicolaides Pathology

South Australia

Kelly Papanoum and Nicholas Wells, SA Pathology (Flinders Medical Centre)

Morgyn Warner and Kija Smith, SA Pathology (Royal Adelaide Hospital)

John Turnidge and Jan Bell, SA Pathology (Women's and Children's Hospital)

Tasmania

Louise Cooley and Rob Peterson, Royal Hobart Hospital

Victoria

Denis Spelman and Amanda Dennison, the Alfred Hospital

Benjamin Howden and Peter Ward, Austin Hospital

Tony Korman and Despina Kotsanas, Monash Medical Centre

Andrew Daley and Gena Gonis, Royal Women's Hospital

Mary Jo Waters and Linda Joyce, St Vincent's Hospital

Western Australia

David McGeachie and Rebecca Wake, PathWest Laboratory Medicine – WA Fremantle Hospital

Barbara Henderson and Ronan Murray, PathWest Laboratory Medicine – WA Queen Elizabeth II Hospital

Owen Robinson, Denise Daley and Geoffrey Coombs, PathWest Laboratory Medicine – WA Royal Perth Hospital

Sudha Pottumarthy-Boddu and Fay Kappler, St John of God Pathology

Table 1: The number and proportion of *E. faecalis* non-susceptible to ampicillin and the non-β-lactam antimicrobials, Australia, 2014

Antimicrobial	Tested	Breakpoint (mg/L)	Non-Susceptible	
			n	%
Ampicillin	522	>8 [*]	3	0.6
		>4 [†]	3	0.6
Vancomycin	523	>4 [‡]	1	0.2
Erythromycin	509	>0.5 [*]	446	87.4
Tetracycline	501	>4 [*]	363	72.5
Ciprofloxacin	477	>1 [*]	122	25.6
Daptomycin	490	>4 [*]	1	0.2
Teicoplanin	521	>8 [*]	0	0
		>2 [†]	0	0
Linezolid	522	>2 [*]	13	2.5
		>4 [†]	0	0
Nitrofurantoin	521	>32 [*]	11	2.1
		>64 [†]	2	0.4
High Level Gentamicin	519	>128 [*]	198	38.2

^{*}CLSI non-susceptible breakpoint

[†]EUCAST non-susceptible breakpoint

[‡]CLSI and EUCAST non-susceptible breakpoint

Table 2: The number and proportion of *E. faecium* non-susceptible to ampicillin and the non- β -lactam antimicrobials, Australia, 2014

Antimicrobial	Tested	Breakpoint (mg/L)	Non-Susceptible	
			n	%
Ampicillin	379	>8 [*]	339	89.5
		>4 [†]	343	90.5
Vancomycin	380	>4 [‡]	175	46.1
Erythromycin	371	>0.5 [*]	351	94.6
Tetracycline	369	>4 [*]	194	52.6
Ciprofloxacin	351	>1 [*]	321	91.5
Teicoplanin	377	>8 [*]	31	8.2
		>2 [†]	33	8.8
Linezolid	378	>2 [*]	2	0.5
		>4 [†]	1	0.3
Nitrofurantoin	377	>32 [*]	289	76.5
		>64 [†]	137	36.2
High Level Gentamicin	377	>128 [*]	233	61.5

^{*}CLSI non-susceptible breakpoint

[†]EUCAST non-susceptible breakpoint

[‡]CLSI and EUCAST non-susceptible breakpoint

Table 3: The number and proportion of major *Enterococcus faecium* (Efm) pulsed-field gel electrophoresis pulsotypes, Australia, 2014, by region

Type	ST	ACT		NSW		NT		Qld		SA		Tas		Vic		WA		Aus	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Efm1	ST203	0		6	4.5	0		1	2.7	0		0		2	2.1	2	4.0	11	2.9
Efm2		1	9.1	3	2.2	0		13	35.1	16	34.8	0		2	2.1	0		35	9.2
Efm75		2	18.2	5	3.7	0		1	2.7	0		0		1	1.1	0		9	2.4
Efm76		1	9.1	13	9.7	0		0		0		0		0		0		14	3.7
Efm74	ST796	0		0		0		0		1	2.2	1	14.3	62	66.0	0		64	16.9
Efm4	ST555	0		0		0		0		6	13.0	0		1	1.1	21	42.0	28	7.4
Efm77		0		0		0		1	2.7	10	21.7	0		0		7	14.0	18	4.7
Efm5	ST17	0		4	3.0	0		3	8.1	0		0		1	1.1	0		8	2.1
Efm18		0		26	19.4	0		0		0		0		0		0		26	6.8
Efm80	ST117	4	36.4	11	8.2	0		1	2.7	0		0		0		0		16	4.2
Efm78	ST761	0		6	4.5	0		1	2.7	0		0		0		0		7	1.8
Efm24	ST192	0		0		0		0		0		2	28.6	4	4.3	0		6	1.6
Efm85	ST80	0		5	3.7	0		0		0		0		0		1	2.0	6	1.6
Efm3	ST341	1		4	3.0	0		0		0		0		0		0		5	1.3
Other		2	18.2	43	32.1	1	100	15	40.5	12	26.1	2	28.6	20	21.3	19	38.0	114	30.0
NT		0		1	0.7	0		1	2.7	0		1	14.3	0		0		3	0.8
ND		0		7	5.2	0		0		1	2.2	1	14.3	1	1.1	0		10	2.6
Total		11	100	134	100	1	100	37	100	46	100	7	100	94	100	50	100	380	100

ACT = Australian Capital Territory; NSW = New South Wales; NT = Northern Territory; Qld = Queensland; SA = South Australia; Tas1 = Tasmania; Vic = Victoria; WA = Western Australia; Aus = Australia, NT = Non Typeable; ND = Not done

Table 4: The number and proportion of major *Enterococcus faecium* (Efm) pulsed-field gel electrophoresis pulsotypes harbouring *vanA/B* genes, Australia, 2014

Pulsotypes	ST	#	vanA		vanB		Not Detected	
Efm1	ST203	11	0	0	4	36.4	7	63.6
Efm2		35	0	0	33	94.3	2	5.7
Efm75		9	0	0	3	33.3	6	66.7
Efm76		14	0	0	11	78.6	3	21.4
Efm74	ST796	64	0	0	64	100	0	0
Efm4	ST555	28	0	0	0	0	28	100
Efm77		18	0	0	17	94.4	1	5.6
Efm5	ST17	8	0	0	0	0	8	100
Efm18		26	24	92.3	1	3.8	1	3.8
Efm80	ST117	16	0	0	0	0	16	100
Efm78	ST761	7	0	0	0	0	7	100
Efm24	ST192	6	0	0	0	0	6	100
Efm85	ST80	6	5	83.3	0	0	1	16.7
Efm3	ST341	5	0	0	4	80.8	1	20.0
Total		253	29	11.5	137	54.1	87	34.4

References

1. Pinholt M, Ostergaard C, Arpi M et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006-2009: a population-based cohort study. *Clin Microbiol Infect* 2014;20(2):145-151.
2. Deshpande LM, Fritsche TR, Moet GJ et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. *Diagn Microbiol Infect Dis* 2007; 58: 163-70.
3. Murray BE. The life and times of the Enterococcus. *Clin Microbiol Rev* 1990; 3: 46-65.
4. Simonsen GS, Smabrekke L, Monnet DL et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. *J Antimicrob Chemother* 2003; 51: 323-31.
5. Treitman AN, Yarnold PR, Warren J et al. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). *J Clin Microbiol* 2005; 43: 462-3.
6. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis* 2009; 48: 1-12.
7. Christiansen KJ, Turnidge JD, Bell JM et al. Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. *Commun Dis Intell* 2007; 31: 392-7.
8. Coombs GW, Daley D, Pearson JC et al. A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia. *Pathol* 2014; 46: 73-5.
9. CLSI. Performance standards for antimicrobial susceptibility testing. *Twenty-fourth informational supplement M100-S24*. Villanova, PA, USA, 2014.
10. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints. 2015.
11. Kulski JK, Wilson RD, Bending R et al. Antibiotic resistance and genomic analysis of enterococci in an intensive care unit and general wards. *Pathol* 1998; 30: 68-72.
12. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol* 1995; 33: 2233-9.
13. Homan WL, Tribe D, Poznanski S et al. Multilocus sequence typing scheme for Enterococcus faecium. *J Clin Microbiol* 2002; 40: 1963-71.
14. Coombs GW, Pearson JC, Daly DA et al. Australian Enterococcal Sepsis Outcome Programme annual report, 2013. *Commun Dis Intell* 2014; 38: E320-6.
15. Coombs GW, Pearson JC, Daley DA et al. Molecular epidemiology of enterococcal bacteremia in Australia. *J Clin Microbiol* 2014; 52: 897-905.